Overcoming bacteriophage insensitivity in Staphylococcus aureus using clindamycin and azithromycinat subinhibitory concentrations. Issue 11 (16th May 2021)
- Record Type:
- Journal Article
- Title:
- Overcoming bacteriophage insensitivity in Staphylococcus aureus using clindamycin and azithromycinat subinhibitory concentrations. Issue 11 (16th May 2021)
- Main Title:
- Overcoming bacteriophage insensitivity in Staphylococcus aureus using clindamycin and azithromycinat subinhibitory concentrations
- Authors:
- Liu, Sha
Zhao, Yin
Hayes, Andrew
Hon, Karen
Zhang, Guimin
Bennett, Catherine
Hu, Hua
Finnie, John
Morales, Sandra
Shearwin, Linda
Psaltis, Alkis J.
Shearwin, Keith
Wormald, Peter‐John
Vreugde, Sarah - Abstract:
- Abstract: Background: Staphylococcus aureus is a pathogen of major concern in both acute infections and chronic conditions such as chronic rhinosinusitis (CRS). Bacteriophage (phage) therapy has recently regained interest for its potential to treat infections caused by antibiotic resistant strains including Methicillin Resistant Staphylococcus aureus (MRSA). However, bacteria can adapt and become resistant to phages. The aim of this study is to determine the potential for antibiotics to overcome phage resistance. Methods: The susceptibility of S. aureus clinical isolates (CIs) to phages J‐Sa36, Sa83 and Sa87 alone or in combination with protein synthesis inhibitor (PSI) antibiotics clindamycin, azithromycin and erythromycin was assessed using plaque spot assays, minimum inhibitory concentration (MIC) assays, double layer spot assays and resazurin assays. The safety and efficacy of subinhibitory PSI antibiotics in combination with phage was tested in a Sprague Dawley rat model of sinusitis infected with a phage resistant S. aureus CI. Results: All three antibiotics at subinhibitory concentrations showed synergy when combined with all 3 phages against S. aureus CIs in planktonic and biofilm form and could sensitize phage‐resistant S. aureus to promote phage infection. The combination of topical subinhibitory clindamycin or azithromycin and phage was safe and could eradicate S . aureus sinonasal biofilms in vivo . Conclusion: Subinhibitory concentrations of PSI antibioticsAbstract: Background: Staphylococcus aureus is a pathogen of major concern in both acute infections and chronic conditions such as chronic rhinosinusitis (CRS). Bacteriophage (phage) therapy has recently regained interest for its potential to treat infections caused by antibiotic resistant strains including Methicillin Resistant Staphylococcus aureus (MRSA). However, bacteria can adapt and become resistant to phages. The aim of this study is to determine the potential for antibiotics to overcome phage resistance. Methods: The susceptibility of S. aureus clinical isolates (CIs) to phages J‐Sa36, Sa83 and Sa87 alone or in combination with protein synthesis inhibitor (PSI) antibiotics clindamycin, azithromycin and erythromycin was assessed using plaque spot assays, minimum inhibitory concentration (MIC) assays, double layer spot assays and resazurin assays. The safety and efficacy of subinhibitory PSI antibiotics in combination with phage was tested in a Sprague Dawley rat model of sinusitis infected with a phage resistant S. aureus CI. Results: All three antibiotics at subinhibitory concentrations showed synergy when combined with all 3 phages against S. aureus CIs in planktonic and biofilm form and could sensitize phage‐resistant S. aureus to promote phage infection. The combination of topical subinhibitory clindamycin or azithromycin and phage was safe and could eradicate S . aureus sinonasal biofilms in vivo . Conclusion: Subinhibitory concentrations of PSI antibiotics could sensitize phage‐resistant S . aureus and MRSA strains to phages in vitro and in vivo . This data supports the potential use of phage‐PSI antibiotic combination therapies, in particular for difficult‐to‐treat infections with phage‐resistant S . aureus and MRSA strains. Abstract : MSSA and MRSA biofilms have reduced sensitivity to antibiotics. Phage can lyse phage sensitive MSSA and MRSA strains but not phage insensitive strains. Subinhibitory protein synthesis inhibitor antibiotics can sensitize phage insensitive S . aureus strains to become sensitive to phage infection resulting in eradication of S . aureus infection in vitro and in vivo. Abbreviations: MSSA, methicillin‐susceptible Staphylococcus aureus ; MRSA, methicillin‐resistant Staphylococcus aureus ; MIC, minimum inhibitory concentration; Abx, antibiotic. … (more)
- Is Part Of:
- Allergy. Volume 76:Issue 11(2021)
- Journal:
- Allergy
- Issue:
- Volume 76:Issue 11(2021)
- Issue Display:
- Volume 76, Issue 11 (2021)
- Year:
- 2021
- Volume:
- 76
- Issue:
- 11
- Issue Sort Value:
- 2021-0076-0011-0000
- Page Start:
- 3446
- Page End:
- 3458
- Publication Date:
- 2021-05-16
- Subjects:
- bacteriophage therapy -- chronic rhinosinusitis -- clindamycin -- S. aureus -- subinhibitory
Allergy -- Periodicals
616.97 - Journal URLs:
- http://estar.bl.uk/cgi-bin/sciserv.pl?collection=journals&journal=01054538 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1398-9995 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/all.14883 ↗
- Languages:
- English
- ISSNs:
- 0105-4538
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0790.945000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 26814.xml